Drug coated balloon angioplasty in elderly patients with small vessel coronary disease
Author(s) -
Dasdo Antonius Sinaga,
Hee Hwa Ho,
Uwe Zeymer,
Matthias Waliszewski,
Fahim Haider Jafary,
Yau Wei Ooi,
Jason Loh,
Julian Tan,
Paul Jau Lueng Ong
Publication year - 2015
Publication title -
therapeutic advances in cardiovascular disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 33
eISSN - 1753-9455
pISSN - 1753-9447
DOI - 10.1177/1753944715598714
Subject(s) - medicine , mace , angioplasty , myocardial infarction , cardiology , atrial fibrillation , balloon , revascularization , population , surgery , percutaneous coronary intervention , environmental health
Background: Coronary angioplasty in advanced age is associated with higher rate of comorbidities and complications. Drug coated balloon only angioplasty (DCBA) has emerged as an alternative to treat small vessel coronary disease (SVCD), of reference vessel diameters <2.8 mm, with shorter duration of dual antiplatelet (DAPT). This is the first study to assess the DCBA efficacy in an elderly population with SVCD.Methods and results: We performed a prospective study of 447 patients (334 patients aged <75 and 113 patients aged ⩾75 years old) acquired from the SeQuent Please Small Vessel ‘Paclitaxel-Coated Balloon Only’ registry. In the older age group, more patients have hypertension (89% versus 77%; p = 0.006), renal insufficiency (21% versus 6%; p < 0.001), atrial fibrillation (17% versus 7%; p = 0.001), and calcified lesions (33% versus 20%; p = 0.006). At 30 days, there was one myocardial infarction requiring target lesion revascularization (TLR) in the younger group. No major adverse cardiac event (MACE) was observed in the older group. At 9 months, the MACE rate in the younger group was 4.2% and 6.1% in the older group ( p = 0.453), with TLR rates at 3.9% and 3.0% ( p = 0.704) respectively. There was no cardiac death observed.Conclusion: DBCA in the elderly with SVCD is as safe and effective compared with younger patients despite more complex anatomy and comorbidities.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom